申联生物预亏2000万二股东套现1.11亿 拟2.37亿并购创新药企业布局

Core Viewpoint - The company, Shenlian Biological, is expanding into the human pharmaceutical sector through the acquisition of a controlling stake in Yangzhou Shizhiyuan Biotechnology, aiming to create a dual business model of "human pharmaceuticals" and "animal health" in response to competitive pressures in its original animal health business [2][7]. Group 1: Acquisition Details - Shenlian Biological plans to invest 237 million yuan to acquire a controlling stake in Shizhiyuan through its wholly-owned subsidiary, Bentiang, via equity transfer and capital increase [3][4]. - The acquisition involves Bentiang paying 31.44 million yuan for a portion of Shizhiyuan's registered capital and investing 206 million yuan to subscribe to Shizhiyuan's new registered capital [3]. - Following the completion of the acquisition, Bentiang will hold 40.65% of Shizhiyuan's equity, and together with its action-in-concert partner, will control 51% of the voting rights [4]. Group 2: Financial Performance and Projections - Shenlian Biological is facing significant financial challenges, with expectations of a net profit loss of 20 million yuan in 2025, following its first loss since going public in 2024 [2][8]. - The company has experienced declining performance in its animal health business, with revenue and gross margins decreasing due to intense competition and lower vaccine prices [8]. - Shizhiyuan, the target of the acquisition, is currently unprofitable, with projected revenues of 164,300 yuan in 2024 and 2.5322 million yuan in 2025, alongside net losses of 1.5652 million yuan and 1.29427 million yuan for the same years [5][7]. Group 3: Strategic Rationale - The acquisition is part of Shenlian Biological's strategy to accelerate its entry into the human pharmaceutical market, leveraging Shizhiyuan's innovative drug development capabilities [7]. - The company aims to integrate Shizhiyuan's research and technology platforms to enhance its human pharmaceutical pipeline and industrial foundation [7]. - The move is seen as a necessary response to the declining performance of Shenlian's existing animal health business, which has faced four consecutive years of revenue decline [7][8].